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ABSTRACT 
Background: Pregnancy-related health complications can pose imminent threats 
to the health of both mother and fetus. Gestational hypertension accompanied by 
proteinuria after 20 weeks’ gestation characterize the condition known as 
preeclampsia, which puts mothers and their fetuses at risk for a number of 
adverse outcomes.  
Significance: From 1987 to 2004, the incidence of preeclampsia rose by 25%. 
Adverse outcomes in the mother-to-be include preterm delivery, acute renal 
failure and maternal death. As a result of preeclampsia, the fetus can suffer 
intrauterine growth restriction, preterm birth and low birth weight.  
Aim: Researchers have explored a number of strategies to predict, prevent and 
manage preeclampsia. This work will explore the various strategies employed 
and documented in the literature. 
Conclusion: Treatments that may be beneficial for the mother (delivering the 
infant), may not necessarily be beneficial for the fetus (may have a young 
gestational age) and vice versa. Therefore, determining the appropriate method 
of handling each case of preeclampsia is critical to the work of the obstetrician, 
and should be decided from evidence-based treatments and management.  
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GLOSSARY 
 
Active management of labor – the constant monitoring and technical control of 
labor to limit its duration. 
Amniotic fluid – the fluid surrounding the fetus in the uterus. 
Angiogenesis – the production of blood vessels. 
Birth weight – weight of neonate at birth in grams. 
Chronic hypertension – elevated blood pressure (greater than 140/90mmHg) 
before week 20 of pregnancy that can persist beyond 6 weeks after the birth of 
the neonate. 
Eclampsia – seizures occurring in pregnancy, accompanied by symptoms of 
preeclampsia, i.e. hypertension and proteinuria.  
Embryo – from conception to 8 weeks’ gestation. 
Fetus – the developing child in the uterus from the end of the embryonic state at 
about the twelfth week of pregnancy, until birth. 
Gestation – the length of time between conception and delivery. 
Gestational age – age of developing fetus counting from conception (usually 
measured in weeks). 
Gestational hypertension – systolic BP of 140 mmHg or higher or diastolic BP 
of 90 mmHg or higher (or both) occurring de novo after 20 weeks’ gestation, and 
disappearing soon after birth. 
Induction – the process of artificially starting labor and keeping it going; also 
referred to as hormone-accelerated labor. 
Intrauterine growth restriction (IUGR) – birthweight less than the 10th 
percentile. 
Low birthweight baby – a baby who weighs below 5 ½ lbs (2500g) immediately 
after birth. 
Neonatal – of or relating to the first 28 days of life (first 4 weeks after birth). 
Oligohydramnios – low urine output. 
xii 
 
Perinatal – the period from the 24th week of gestation to one week following 
delivery. 
Preeclampsia – gestational hypertension combined with proteinuria detected 
after 20 weeks of gestation; pregnancy-induced hypertension and proteinuria. 
Placental abruption – (i.e. abruption placentae) premature separation of the 
placenta (the organ that nourishes the fetus) from the uterine wall prior to 
delivery that can lead to IUGR and hemorrhage. 
Prenatal – before delivery. 
Preterm birth – birth before 37 wk of gestation. 
Prophylaxis – a measure taken to prevent disease by specified means or 
against a specified disease. 
Proteinuria – 300 mg of protein or more in a 24-h urine specimen or a positive 
reaction (1) on a midstream urine specimen; or 30mg/mmol spot urine 
protein/creatinine ratio. 
Soluble fms-like tyrosine kinase-1 – a tyrosine kinase protein that disables 
proteins that cause blood vessel growth. 
Term – completing a full-length pregnancy; about 38 to 42 weeks from the last 
menstrual period, i.e. 37 completed weeks of gestation. 
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I. INTRODUCTION 
A. Significance 
Hypertension is the 3rd leading cause of pregnancy-related deaths in the 
United States, after hemorrhage and embolism (Koonin et al., 1997; MacKay et 
al., 2001). Of the 500,000 maternal deaths that occur worldwide each year, it is 
estimated that between 10-15% are caused by hypertensive disorders of 
pregnancy (Khan el al., 2006; Leslie et al., 2011). Approximately 5-10% of all 
pregnant women will develop some form of hypertension (MacKay et al., 2001). 
Essential hypertension, which develops without apparent cause, accounts for 
about 90% of these cases, while secondary causes, such as kidney diseases 
and endocrine and connective tissue disorders, are responsible for the rest 
(Koren, 2004). Pregnancy complications related to hypertension account for 15% 
of antenatal hospitalizations (MacKay et al., 2001). 
Mothers who develop hypertension for the first time during their pregnancy 
are at greater risk for acute renal failure and cardiovascular complications among 
other problems. This de novo gestational hypertension (GH), when accompanied 
by proteinuria, is referred to as preeclampsia (PE). Preeclampsia is a complex 
clinical syndrome characterized by elevated blood pressure, proteinuria and 
occasionally pathologic edema all that appear after 20 weeks’ gestation, which is 
during the 2nd trimester. Preeclampsia develops in 6-8% of pregnancies, 70% of 
which are first-time pregnancies (Thepregnancyzone.com, 2012). Preeclampsia 
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can be either mild or severe, or can develop into full-blown eclampsia for which 
seizures are a common symptom (Langenveld et al., 2011).  
Preeclampsia can lead to adverse outcomes in the fetus including low 
birthweight, premature birth, and still birth. In a population-level study of the 
secular trends of preeclampsia, eclampsia and gestational hypertension, it was 
found that from 1987 to 2004, the rate of preeclampsia rose by 25% (FIGURE 1) 
(Wallis et al., 2008). This could partly be due to the rise in the number of older 
mothers and the number of multiple births in which preeclampsia occurs more 
frequently (Sutton, 2009). However, the overall proportion of pregnancies with 
GHduring the study period increased significantly (184%), though this can be 
partly attributed to the change in definition over the years (Wallis et al., 2008). 
Rates of eclampsia showed a non-significant decrease of 22%.   
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Crude incidence rates, gestational hypertension and preeclampsia, 
1987-2004, 3-year moving averages 
Gestational Hypertension Preeclampsia
FIGURE 1 | Age-adjusted incidence per 1,000 deliveries for women with gestational 
hypertension (P < 0.0001) or preeclampsia (P = 0.009) with 3-year moving averages, 1987–2004. 
Refer to Appendix A for a table with the weighted number of cases and crude incidence rates 
accompanying this figure. Figure amended from Wallis et al., 2008. 
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B. Diagnosis 
In order for a diagnosis of preeclampsia to be made, both hypertension 
and proteinuria must be present. Edema was once included in the criteria for 
diagnosing PE; however, due to the difficulty in objectively quantifying edema, it 
is no longer a required element for diagnosis of PE. Occurring at or after 20 
weeks’ gestation, preeclampsia is defined as a systolic pressure of greater than 
or equal to 140mmHg or diastolic pressure of greater than or equal to 90mmHg, 
or both, accompanied by proteinuria in previously normotensive women (TABLE 
1). Regular urine and blood pressure readings are necessary to diagnose and 
treat this problem in its early stages. During monthly prenatal visits, taking urine 
samples is a routine procedure (North et al., 2011). Three approaches are 
currently used in the clinic to determine excessive excretion of protein: the 
qualitative dipstick, the quantitative 24h urine collection, and the 
protein/creatinine or albumin/creatinine ratios on a single voided urine 
(Lindheimer and Kanter, 2010).  
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TABLE 1. Essentials of Diagnosis of Moderate to Severe Preeclampsia. 
     Measurements 
  ................................................................................................... 
Feature Normal  Preeclampsia Severe PE 
......................................................................................................................... 
SBP  110-120mmHg >140mmHg*  >160mmHg*  
......................................................................................................................... 
DBP  70-80mmHg  >90mmHg*  >110mmHg* 
......................................................................................................................... 
Proteinuria 
24h Urine*   <300mg  > 0.3-5g  >5g 
Dipstick*     1+   2+   4+   
......................................................................................................................... 
*On at least two occasions 4h to 6h apart, developing in previously normotensive 
women with proteinuria of 300 mg or more in 24 h, or two readings of at least 2+ 
on dipstick analysis of midstream or catheter urine specimens if 24-h urine 
collection was not available. 
Sources: McPhee and Papadakis, 2011; Yu et al., 2011; North et al., 1999. 
 
 
1. Timing of Onset of Disease 
The timing in which a pregnant woman presents with preeclampsia is 
influenced by the various biochemical and clinical features that contribute to the 
development of the disease (Meler et al., 2010). Early-onset PE (occurring 
between 20+0 and 33+6* weeks’ gestation) is associated with placental 
insufficiency due to defective trophoblastic invasion. The late-onset form 
(occurring at or after 34+0 weeks) is more prevalent. Greater than seventy 
percent (70%) of preterm infants are born between 34+0 and 37+0 weeks 
gestation, thus late preterm infants account for the vast majority of preterm births 
                                                          
*
 Base number refers to the number of weeks’ gestation, whereas superscript refers to the 
number of days’ gestation. For example: 21
+2 
refers to 21 weeks’ and 2 days’ gestation. 
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(Langenveld et al., 2011). Mothers can also develop preeclampsia late 
postpartum, anywhere between 48 hours and 6 weeks after delivery (McPhee 
and Papadakis, 2011). 
  
C. Etiology 
Preeclampsia is a multisystem disorder with multiple factors contributing to 
its development. Although there are several postulations for what causes 
preeclampsia, there is still controversy on what actually causes it. The 
pathophysiology of preeclampsia involves defective trophoblastic invasion of the 
maternal spiral arteries during early gestation (Yu et al., 2011). The proteinuria 
reflects kidney malfunction and damage. The middle panel of FIGURE 2 
illustrates the inadequate penetration into the myometrium; although this can also 
be showing what could be the initial stages of normal invasion. These events 
affect the uterine environment and thus have effects on fetal development and 
outcome. 
Immunological and inflammatory processes are suspected to be involved 
in the development of PE, specifically as a result of defective trophoblastic 
invasion of the myometrium (Hofmeyr et al., 2011). In normal receptive 
endometrium, the maternal immune marker pentraxin-3 is known to be present; 
however, expression is abnormally high in as early as the first trimester in women 
who develop preeclampsia. This supports the hypothesis that there is an 
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excessive maternal inflammatory response to pregnancy in the cause of pre-
eclampsia (Hofmeyr et al., 2011). 
 
FIGURE 2 | Inadequate vs. Adequate Trophoblastic Invasion of the Myometrium 
during Pregnancy. Trophoblastic invasion is instrumental in increasing blood flow 
through the maternal uterine arteries during pregnancy. The left panel shows the 
uninvaded spiral arteries of a non-pregnant woman. The middle panel shows 
inadequate invasion of the media by trophoblasts characteristic of pathologic 
conditions of pregnancy such as preeclampsia and IUGR. This will lead to decreased 
blood flow that can lead to ischemic placenta, systemic endothelial dysfunction in 
the mother and ultimately preeclampsia. The right panel shows adequate invasion of 
the trophoblastic cells into the myometrium, characteristic of a normal pregnancy.  
(Bell, 2004) 
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D. Differential Diagnosis  
Preeclampsia and eclampsia can mimic and be confused with many other 
diseases, particularly when preexisting conditions are present. In addition, there 
are several other disorders that can also lead to symptoms that are often 
associated with preeclampsia. Chronic hypertension, chronic kidney disease, and 
immune thrombocytopenia are among the diseases that can be mistaken for PE 
in pregnancy (TABLE 2). 
TABLE 2. Other diseases that are easily confused with preeclampsia. 
............................................................................................................................... 
Chronic hypertension 
............................................................................................................................... 
Chronic kidney disease 
............................................................................................................................... 
Primary seizure disorders 
............................................................................................................................... 
Gallbladder and pancreatic disease 
............................................................................................................................... 
Immune thrombocytopenia 
............................................................................................................................... 
Hemolytic-uremic syndrome 
............................................................................................................................... 
Source: McPhee and Papadakis, 2011. 
 
Meanwhile, arterial embolism or thrombosis, seizure disorder, and 
metastatic gestational trophoblastic disease can be mistaken for eclampsia 
(TABLE 3). Nevertheless, preeclampsia should be considered a possibility in any 
women beyond 20 weeks of gestation who is presenting with preeclamptic signs 
and symptoms (McPhee and Papadakis, 2011). In such cases where diagnosis is 
uncertain, it may be helpful to determine uric acid values because hyperuricemia 
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in pregnancy is typically only common in gout, kidney disease or preeclampsia 
(McPhee and Papadakis, 2011). 
TABLE 3. Differential diagnosis of eclampsia. 
........................................................................................................................... 
Cerebrovascular accidents  Previously undiagnosed brain tumors 
........................................................................................................................... 
Hemorrhage     Metastatic gestational trophoblastic  
     disease 
........................................................................................................................... 
Ruptured aneurysm    Metabolic diseases 
........................................................................................................................... 
Arterial embolism or thrombosis  Reversible posterior  
     leukoencephalopathy syndrome 
........................................................................................................................... 
Cerebral venous thrombosis   Catastrophic antiphospholipid syndrome 
........................................................................................................................... 
Seizure disorder   Thrombotic thrombocytopenic  
      purpura 
........................................................................................................................... 
Angiomas    Postdural puncture syndrome 
........................................................................................................................... 
Hypertensive encephalopathy  Cerebral vasculitis 
........................................................................................................................... 
Hypoxic ischemic encephalopathy 
........................................................................................................................... 
Source: Sibai, 2009. 
 
E. Risk Factors 
Understanding the underlying mechanisms and conditions that might lead 
to preeclampsia and associated conditions is critical to identifying mothers who 
are at risk for developing PE. Currently, the strongest predictor of a mother 
developing preeclampsia in a current pregnancy is having had developed it in a 
previous pregnancy. History of preeclampsia in primary relatives, i.e. mothers 
and sisters, also puts women at greater risk of developing PE themselves 
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(Koren, 2004). Incidence of preeclampsia is increased with multiple pregnancies, 
chronic hypertension, diabetes, kidney disease, collagen-vascular and 
autoimmune disorders, and gestational trophoblastic disease (McPhee and 
Papadakis, 2011). First-time mothers are more frequently affected (McPhee and 
Papadakis, 2011). One study found having a BMI over 30, hypertension during 
the incident pregnancy, and having a previous cesarean section are all predictive 
factors of developing preeclampsia in the late postpartum period (Koren, 2004). 
Women of African American descent are also at greater risk than their white 
counterparts. Although their sample was quite small, the researchers postulate 
that their findings were still significant (Larsen et al., 2012).TABLE 4 indicates 
other factors associated with higher risk of developing PE.  
High-risk nulliparous women represent the largest proportion of pregnant 
women at risk for PE (Bujold, 2011). Rates of preeclampsia and eclampsia 
increase with maternal age, and are also higher during the teenage years 
(MacKay et al., 2001). Mothers considered at-risk are those who bear the risk 
factors listed in TABLE 4, have positive Doppler ultrasonography or, other 
predictive test (these tests will be described in the “Prediction” section). Low-risk 
mothers are considered to be those without any risk factor or positive predictive 
tests (Trivedi, 2011). A Finnish study found that the stress of daily living was not 
associated with increased risk of PE, whereas depression, anxiety, and stress 
from strenuous work were (Koren, 2004). 
11 
 
 
TABLE 4. Risk factors for preeclampsia. 
............................................................................................ 
High blood pressure before becoming pregnant 
............................................................................................ 
Previous with high blood pressure or preeclampsia 
............................................................................................ 
Obesity (BMI of 30 kg/m2 or greater) 
............................................................................................ 
Younger than age 20 or older than age 40 
............................................................................................ 
Pregnant with more than one baby 
............................................................................................ 
Certain health conditions, such as 
Diabetes (pre-gestational or gestational) 
Preexisting kidney disease 
Rheumatoid arthritis 
Lupus (autoimmune)  
Scleraderma 
Underlying blood clotting disorders 
Cardiovascular disease 
............................................................................................ 
Primiparity (first-time mother) 
............................................................................................ 
Maternal primary history (i.e. sister or mother with PE) 
............................................................................................ 
Smoked prior to pregnancy  
............................................................................................ 
Being Black or African American 
............................................................................................ 
Sources:  Sutton, 2009; Bohn et al., 2011; ACOG, 2000;  
England et al., 2002. 
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F. Adverse Outcomes 
Gestational hypertension accompanied by proteinuria presents a number 
of risks to both mother and infant (TABLE 5). Compared with normotensive 
mothers, mothers with preeclampsia are at greater risk for placental abruption, 
acute renal failure, and maternal mortality, among a number of other serious 
complications. Women with moderate to severe PE can develop serious life-
threatening complications rapidly without warning. Thus, they and their fetuses 
should be closely and continuously monitored. 
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TABLE 5. Adverse Outcomes Related to Severe Preeclampsia. 
Maternal Complications Fetal Complications 
Acute renal failure 
.................................................................... 
HELLP syndrome 
.................................................................... 
Preterm delivery 
.................................................................... 
Placental abruption (cause of 
hemorrhage) 
.................................................................... 
Caesarean section 
.................................................................... 
Proteinuria 
.................................................................... 
Edema (i.e. pulmonary) 
.................................................................... 
Central nervous system 
dysfunction 
.................................................................... 
Hepatocellular injury 
.................................................................... 
Thrombocytopenia (low platelet 
count <150x109/L) 
.................................................................... 
Oliguria (low urine output) 
.................................................................... 
Cardiovascular complications 
.................................................................... 
Intensive care unit admission 
.................................................................... 
Eclampsia 
.................................................................... 
Admission to ICU > 7 days 
.................................................................... 
Seizures 
.................................................................... 
Coma 
.................................................................... 
Maternal death 
.................................................................... 
Bleed through orafices 
.................................................................... 
Premature birth 
.................................................................... 
Low birthweight 
.................................................................... 
Intrauterine growth restriction 
.................................................................... 
 Placental abruption (i.e. deprive 
fetus of oxygen and nutrients) 
.................................................................... 
Small for gestational age 
.................................................................... 
Respiratory distress syndrome 
.................................................................... 
Admission to NICU> 7 days 
.................................................................... 
Metabolic morbidities (i.e. 
hypoglycemia) 
.................................................................... 
 Gastrointestinal morbidities (i.e. 
hyperbilirubinemia) 
.................................................................... 
 Necrotizing enterocolitis – any 
stage 
.................................................................... 
 Stillbirth or death before discharge 
from hospital 
.................................................................... 
 SBP> 95th percentile during 
childhood 
.................................................................... 
 DBP> 95th percentile during 
childhood 
.................................................................... 
 
 
 
Sources: Langenveld et al., 2011; Hofmeyr et al., 2010; Barton et al., 2008; MacKay 
et al., 2001. 
Abbreviations: ICU, intensive care unit; NICU, neonatal intensive care unit; SBP, 
systolic blood pressure; DBP, diastolic blood pressure. 
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1. Signs and Symptoms 
Variables that are reliable indicators of severity of preeclampsia include 
status of blood pressure control, evidence of increasing organ damage in the 
liver and hematological systems, evidence of falling glomerular filtration rate, and 
signs of neurological involvement (Lindheimer and Kanter, 2010). 
TABLE 6. Signs and symptoms consistent with preeclampsia. 
................................................................................................................................. 
Right upper quadrant pain 
................................................................................................................................. 
Epigastric pain  
................................................................................................................................. 
Retrosternal chest pain 
................................................................................................................................. 
Nausea and vomiting 
................................................................................................................................. 
Shortness of breath/congestive heart failure 
................................................................................................................................. 
Headaches (not responsive to analgesics) 
................................................................................................................................. 
Visual changes 
................................................................................................................................. 
Altered mental status 
................................................................................................................................. 
Bleeding from mucosal membranes 
................................................................................................................................. 
Overactive reflexes (hyperreflexia) 
................................................................................................................................. 
Jaundice 
................................................................................................................................. 
Edema (swelling in the face or hands) 
................................................................................................................................. 
Sudden weight gain (3 pound/week or more) 
................................................................................................................................. 
Source: McPhee and Papadakis, 2011.  
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Preeclampsia exerts its effects on six major sites of the body: the central 
nervous system, kidney, liver, hematologic, vascular, and fetal-placental unit 
(McPhee and Papadakis, 2011). TABLE 7 describes the indicators of mild versus 
severe preeclampsia-eclampsia in each of these sites. 
Source: McPhee and Papadakis, 2011. 
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
LDH, lactate dehydrogenase; LFTs, liver function tests. 
 
  
TABLE 7. Indicators of mild versus severe preeclampsia-eclampsia.  
Site Indicator Mild to Moderate Severe 
Central 
nervous 
system 
Symptoms and 
signs 
Hyperreflexia Seizures 
Blurred vision 
Scotomas 
Headache 
Clonus 
Irritability 
Kidney 
Proteinuria 
 
 
 
Uric acid 
Urinary output 
0.3-5g/24h or 
catheterized urine 
with 2+ protein 
 
>4.5mg/dL 
>30mL/h 
>5g/24h or 
catheterized 
urine with 4+ 
protein 
>4.5mg/dL 
<30mL/h 
Liver 
Liver enzymes: 
AST, ALT, LDH 
Normal Elevated LFTs 
Epigastric pain 
Ruptured liver 
Hematologic 
Platelets 
Hemoglobin 
> 100,000/mcL 
Normal range 
< 100,000/mcL 
Elevated 
Vascular 
Blood pressure 
Retina 
< 160/110mmHg 
Arteriolar spasm 
> 160/110mmHg 
Retinal 
hemorrhages 
Fetal-
placental 
unit 
Growth restriction 
Oligohydramnios 
Fetal distress 
Absent 
Absent 
Absent 
Present 
Present 
Present 
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In severe PE, symptoms are more dramatic and persistent than in mild to 
moderate PE. Hemolysis, elevated liver enzymes, and low platelet count 
(HELLP) syndrome is a form of severe preeclampsia named for the resulting 
complications (Ciantar and Walker, 2011). HELLP syndrome occurs in 10-20% of 
cases of severe preeclampsia, and in 0.5-0.9% of all pregnancies (Haram et al., 
2009). Thrombocytopenia, which is low platelet count, if present, can progress to 
disseminated intravascular coagulation in which coagulation and fibrinolysis are 
inappropriately begun resulting in systemic generation of thrombin. This excess 
thrombin will then cause thrombosis throughout the body leading to depletion of 
antithrombotic agents and eventually to hemorrhage (McPhee and Papadakis 
2011; AHDC). Furthermore, women may experience severe epigastric pain 
resulting from hepatic subcapsular hemorrhage with significant stretch or rupture 
of the liver capsule (McPhee and Papadakis, 2011). 
Preeclampsia can lead to a number of metabolic and gastrointestinal 
alterations in the fetus, including hypoglycemia and hyperbilirubinemia, 
respectively (Barton and Sibai, 2008). This syndrome can also lead to 
inadequate blood flow through the blood vessels in the uterus, potentially 
depriving the fetus of oxygen and nutrients causing intrauterine growth 
restriction. Many of the morbidities seen in fetuses are driven mainly by the 
gestational age (GA) of the fetus as well as the mode of delivery,† i.e. vaginal vs. 
cesarean (Langenveld et al., 2011). Pregnant women suffering from 
                                                          
†
More about the effects of the mode of delivery in the Management section. 
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preeclampsia who complain of headaches and blurred vision have approached 
the severe end of the disease. On the extreme level of severe preeclampsia, 
mothers can experience a graver range of symptoms including dysfunction of the 
central nervous system leading to seizures and hepatocellular injury. TABLE 7 
provides a detailed list of signs and symptoms known to be present in mothers 
who have developed severe preeclampsia. Specific causes of death among 
women who died from preeclampsia or eclampsia range from cerebrovascular 
hemorrhage to renal or hepatic failure to HELLP syndrome (TABLE 8).   
  
TABLE 8. Specific Causes of Death Among Women Who Died of 
Preeclampsia or Eclampsia. 
Cause of death 
Percent of Deaths 
PE Eclampsia Total 
Cerebrovascular events 17.3 21.4 38.7 
Cerebrovascular hemorrhage 15.8 18.8 34.7 
Cerebral edema 1.1 1.8 2.9 
Cerebral embolus 0.4 0.8 1.1 
Renal or hepatic failure 7.2 5.4 12.5 
HELLP syndrome 4.8 2.3 7.1 
Other complications of 
Hypertension 
13.9 11.8 25.7 
Not specified hypertension 7.6 8.3 15.9 
Preeclampsia and eclampsia 50.8 49.2 100.0 
Source: MacKay et al., 2001. 
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2. Postpartum Complications  
Preeclampsia in pregnancy may reveal a woman’s risk for chronic disease and 
other negative conditions later in life (Rich-Edwards, 2012). Women who 
developed preeclampsia during pregnancy have a greater risk of having cardiac 
arrest in the 10 to 20 years following the incident pregnancy, compared to 
women who did not have PE (Koren, 2004). That there is a chance a woman can 
still develop preeclampsia may up to 6 weeks following her delivery (McPhee and 
Papadakis, 2011) calls for continuous monitoring of at-risk women even after 
delivery. 
 
II. AIM 
This work will discuss predictive measures, describe prevention 
measures, explore methods of treating and managing preeclampsia, and 
recommend approaches to treat cases of preeclampsia. 
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III. LITERATURE REVIEW 
A. Prediction 
Many models have been explored and proposed to attempt to accurately 
predict which pregnant women will develop preeclampsia. The more 
comprehensive models that incorporate both biochemical and biophysical tests 
along with maternal characteristics are more promising. Although the scientific 
community has yet to come to discover a wide-ranging predictive model, there 
are several methods that have demonstrated promise for successfully predicting 
preeclampsia development. TABLE 9 lists the World Health Organization’s 
suggestion for prediction and screening tests. 
 
 
TABLE 9. Suggested criteria for a prediction test: World Health 
Organization systematic review 2004. 
................................................................................................................................. 
Simple 
................................................................................................................................. 
Rapid 
Non-invasive 
Inexpensive 
Easy to carry out early in gestation 
Imposes minimal discomfort or risk 
Widely available technology 
Valid 
Reliable 
Reproducible 
................................................................................................................................. 
High likelihood ratio for a positive result (>10) 
Low likelihood ratio for a negative result (<0.1) 
................................................................................................................................. 
Source: WHO Report, 2004. 
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1. Biomarkers 
The use of pregnancy-related biomarkers has gained much popularity by 
researchers in predicting preeclampsia. A number of promising biomarkers for 
development of the disease have been identified and are currently being 
explored for the prediction of preeclampsia and associated hypertensive 
conditions during pregnancy (Papageorghiou and Roberts, 2005; Madazli et al., 
2005). The biomarkers listed in TABLE 10 that are used in predicting 
preeclampsia are gathered from maternal peripheral venous blood samples to 
measure mid-trimester‡ serum levels. Women who went on to develop 
preeclamsia tended to have significantly higher second-trimester levels of serum 
activin A and fibronectin and S/D ratios as well as significantly lower levels of 
PlGF than mothers who did not develop PE, i.e. remained normotensive 
(Madazliet al., 2005).  
                                                          
‡
 Mid-trimester is the same as second-semester. 
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TABLE 10. Predicting preeclampsia in mothers between 21+0 to 25+6 
weeks’gestation. 
Higher in Preeclampsia Lower in Preeclampsia 
Soluble endoglin Placental growth factor (PlGF) 
Serum Activin A 
Transforming growth factor beta 1 
(TGF-β1) 
Fibronectin  
Vascular endothelial growth factor (VEGF)  
Soluble Fms-like tyrosine kinase 1 (sFlt-1)  
Source: Madazliet al., 2005. 
 
Lim et al. discovered that preeclampsia may be effectively predicted by 
calculating the ratio of four select angiogenesis-related factors: sFlt-1, 
solubleendoglin, PIGF, and TGF-β1 (Lim et al., 2008). Similar to Madazli et al., 
the levels of these factors were collected in the second trimester from both 
women who subsequently developed PE and those who did not. The researchers 
found that sFlt-1 and solubleendoglin levels are higher in preeclamptic women 
than in normotensive women where as PlGF and TGF-β1 levels are lower.  
 
2. Uterine Artery Doppler 
Leslie et al. conducted an exhaustive review of the literature on predicting 
pre-eclampsia in appendix (Leslie el al., 2011). Their findings on screening tests 
that have been proposed for identifying mothers who will develop preeclampsia 
are summarized in APPENDICES B1 and B2. The uterine artery pulsatility index 
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(UAPI) is a measure of blood flow through the uterine arteries and can be 
assessed by performing a Doppler ultrasound. In patients who subsequently 
developed preeclampsia, the UAPI was increased in the late second trimester 
likely as a result of the defective trophoblastic invasion (Yu et al., 2011). 
Improvements in technology over the past several decades allow for greater 
assessment of the flow of blood through the uterine artery. Abnormal uterine 
artery Doppler waveform uterine artery Doppler evaluation has been studied 
extensively for the prediction of preeclampsia and intrauterine growth restriction 
that reflects the involvement of a defective trophoblastic invasion. Uterine artery 
Doppler allows for the prediction of preeclampsia based on the involvement of a 
defective trophoblastic invasion (Meler et al., 2010). Combining UAPI and serum 
biomarkers provides the greatest predictive value for preeclampsia. 
 
B. Prevention 
As preeclampsia can develop at any time around 20 weeks’ gestation, 
appropriate measures such as blood pressure readings and urine samples 
should be taken regularly and begin as soon as possible to detect signs of PE 
(Leslie et al., 2011). Careful monitoring of patients will not necessarily prevent 
preeclampsia, however it will allow for early diagnosis when it does occur. 
Preventing preeclampsia would reduce a great deal of stress on the potentially 
affected mother and the health care system which cares for her. This section will 
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discuss preventive measures that have been explored and the rationale for their 
use. 
 
1. Combined Vitamin C and E Supplementation 
In pregnant women with preeclampsia, levels of free radicals are 
increased and levels of antioxidants, which scavenge free radicals, are 
decreased. These imbalanced alterations are a result of impaired placental 
development in early pregnancy (Basaran et al., 2010) and contribute to 
oxidative stress which in turn likely contributes to the development of 
preeclampsia. This presents the rationale for use of the antioxidant preventive 
measure of the combined vitamin supplements. Randomized control studies 
have been published that studied the preventive qualities of combined vitamin C 
and E supplements (vitCE) during pregnancy (Polyzos et al., 2007). Timing, 
dosage and location of injection were investigated to determine the effectiveness 
of this preventive measure. Results from the majority of these studies show that 
there are no significant differences between vitCE and placebo groups (Rumbold 
et al., 2006; Polyzos et al., 2007; Basaran et al., 2010; Conde-Agudelo et al., 
2011). Thus, there is no reduction in risk for preeclampsia using this combined 
antioxidant regimen during pregnancy. Furthermore, an association has been 
found in which it may slightly increase the risk of preterm birth in the neonate 
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(Poston et al., 2006). Thus, combined vitamin C and E supplements during 
pregnancy are not recommended for the prevention of preeclampsia. 
 
2. Dietary and Lifestyle Measures 
 Research has shown that there are no benefits in preventing preeclampsia 
by taking particular dietary measures—such as salt restriction, reduced protein or 
energy intake, garlic or fish oils (Leslie et al., 2011). In morbidly obese women 
(BMI > 35), losing weight before getting pregnant may reduce their risk of 
developing PE; their odds ratio of developing the disease is 7.2 over women who 
are not obese (Leslie et al., 2011). Weight loss can also help women who are 
obese or overweight. On the other hand, exercise in moderation can also modify 
the risk of developing PE, possibly by boosting immune functions and reducing 
chronic inflammation (Lu, 2009). 
 
3. Calcium Supplementation 
 Calcium (Ca2+) supplements have shown to be successful in reducing the 
incidence of preeclampsia in high-risk women without a history of the syndrome 
and women in countries where there is low calcium intake (Hofmeyr et al., 2011). 
Supplementation of Ca2+ would need to begin at 34+0 weeks’ gestation or less 
(specifically in the first half of pregnancy). When supplementation begins in the 
first trimester, it may be able to prevent endothelial dysfunction associated with 
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PE; whereas, if Ca2+ supplementation is begun in the second half of pregnancy, 
its effect might be reducing blood pressure directly. Calcium supplementation 
affects uteroplacental blood flow by lowering the resistance index (RI) in uterine 
and umbilical arteries (Sanchez-Ramos et al., 1995). 
 
4. Low-Dose Aspirin Therapy 
There is currently no consensus on the efficiency of low dosage of aspirin 
(LDA) being administered to women at risk of developing preeclampsia. Factors 
that should be contemplated when trying to explain the heterogeneity between 
results in studies include: 1. the dosage and time of day for LDA administration, 
2. the population investigated, and 3. the intervention time during pregnancy.  
A meta-analysis of low-dose aspirin for the prevention of preeclampsia 
that included results from over 28,000 women found that LDA has a small but 
significant effect (RR=0.79, 95% CI 0.65-0.97) on preventing PE among women 
considered to be at high risk for developing PE (Trivedi, 2011). The dosage of 
aspirin administered in a daily regime to prevent preeclampsia ranged from 50 to 
150 mg. Thus, the use of LDA in high-risk women is associated with the modest 
benefit of a 21% reduction in the prevalence of PE. On the contrary, LDA 
preventive effects were insignificant in low-risk women (RR=0.86, 95% CI 0.64-
1.17). 
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A recent meta-analysis indicated that starting LDA administration before 
16+0 weeks of gestation is associated with a statistically significant 53% reduction 
in the risk of preeclampsia (Bujold et al., 2010). TABLE 11 highlights the 
differences in results depending on whether the timing of administration before or 
after 16+0 weeks’ gestation. Bujold et al. concluded that aspirin therapy in low 
doses begun in the first trimester of pregnancy, more specifically started at 16+0 
weeks’ gestation or earlier, is efficient in reducing the incidence of preeclampsia, 
among women identified to be at moderate or high risk for PE (Bujold et al., 
2012). LDA started that early also is associated with a reduction in the incidence 
of IUGR, preterm labor and gestational hypertension (Bujold et al., 2010).   
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TABLE 11. Relative Risk of Outcomes Associated with the Use of Low-Dose 
Aspirin According to Gestational Age at Initiation of Intervention. 
 
Effects of low-dose aspirin started at or before 16 weeks gestation. 
Adverse 
Outcome 
RR 95% CI 
No. of 
Trials 
No. of 
Participants 
Prevalence 
Treated Control 
Preeclampsia 0.47 *0.34-
0.65 
9 764 9.3%  21.3% 
Severe PE 0.09 *0.02-
0.37 
3 278 0.7% 15.0% 
Gestational 
hypertension 
0.62 †0.45-
0.84 
7 548 16.7% 29.7% 
Preterm birth 0.22 *0.10-
0.49 
4 387 3.5% 16.9% 
IUGR 0.44 †0.30-
0.65 
5 414 7.0% 16.3% 
Placental 
abruption 
0.62 0.08-
5.03 
4 360 1.1% 3.3% 
Effects of low-dose aspirin started after 16 weeks. 
Adverse 
Outcome 
RR 95% CI 
No. of 
Trials 
No. of 
Participants 
Prevalence 
Treated Control 
Preeclampsia 0.81 0.63-
1.03 
18 10,584 7.3% 8.1% 
Severe PE 0.26 0.05-
1.26 
2 669 0.6% 2.4% 
Gestational 
hypertension 
0.63 †0.47-
0.85 
14 4,303 11.6% 15.0% 
Preterm birth 0.90 †0.83-
0.97 
16 10,398 18.6% 20.8% 
IUGR 0.92 0.78-
1.10 
10 1,381 13.4% 16.0% 
Placental 
abruption 
1.56 0.96-
2.55 
6 3,583 2.3% 1.4% 
Source: Bujold et al., 2010. *P<0.001 † P<0.05 
Abbreviations: RR, relative risk; CI, confidence interval; IUGR, intrauterine growth 
restriction. 
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C. Management 
The chief requirements for successful management of preeclampsia are 
early diagnosis, close follow-up, and timely delivery (Koren, 2004). When the 
severity of preeclampsia dramatically increases, rapid measures are required to 
attain a positive and healthy outcome for both mother and fetus. The only sure 
way to cure a mother of her preeclampsia is to deliver the fetus and placenta, 
and this should be done at a time as favorable as possible for the survival of the 
infant (McPhee and Papadakis, 2011). The younger the GA the greater the risk 
of fetal morbidities and mortality, and cesarean section also presents a higher 
risk of fetal morbidities and mortality than does vaginal delivery. Vaginal delivery 
is preferred essentially because it involves less blood loss and requires fewer 
coagulation factors than a cesarean section (McPhee and Papadakis, 2011). 
Symptoms usually resolve within a few days and the mother is cured, but may 
require temporary use of blood pressure medications if elevated BP persists. 
 
1. Labor Induction 
Depending on the gestational age of the fetus and condition of the mother, 
providers have to make educated decisions on whether to use temporizing 
management that will prolong the gestation of the fetus, or to deliver right away in 
order to minimize danger to the mother. The objectives of treatment are to 
prolong pregnancy in order to allow fetal lung maturity, all the while preventing 
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progression to severe disease and eclampsia (McPhee and Papadakis, 2011). 
On average, labor induction in aggressive management is no longer than 48 
hours after detection of eclampsia. Strong indications for delivery of the fetus 
include epigastric pain, severe range blood pressures, thrombocytopenia, and 
visual disturbances (McPhee and Papadakis, 2011), thus, typically severe 
preeclampsia will require delivery. 
 
2. Expectant Management 
Expectant management, i.e. temporizing management, involves providing 
the expecting mother with antihypertensive treatments that may be harmful to the 
fetus, although this management will also prolong the gestational age of the fetus 
(Brichant et al., 2010). A major benefit of expectant management is prolonging 
the gestational age of the fetus allowing for fetal lung maturation (Brichantet al., 
2010). This is done while trying to lower the woman’s blood pressure into a safe 
range. Practitioners must weigh the risks and benefits of staying in the uterus 
versus being born preterm. Particularly when used for early onset preeclampsia, 
i.e. before 32 weeks’ gestation, temporizing management requires close 
monitoring of mother and fetus (Langenveld et al., 2011).  
In patients with early-onset preeclampsia, expectant management 
improves neonatal outcome in selected cases and decreases neonatal care 
intensive unit admittance and neonatal respiratory distress (Meler, 2010).Based 
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on a review of studies involving 1677 women between 24+0 and 33+6 weeks’ 
gestation and 115 women under 24 weeks gestation, Sibai and Barton suggest 
that expectant management is safe for those women who develop severe 
preeclampsia beyond 24 weeks if conducted in a suitable hospital. This is likely 
due to the viability of the fetus beginning at 24+0 weeks GA. EM among this 
select group of women is also associated with improved neonatal outcome. 
However, for those with a GA below 24 weeks, prolonging the pregnancy was not 
only associated with little benefit for the fetus, but also with high risk of maternal 
morbidity. These two researchers propose selecting appropriate candidates for 
expectant management based on maternal condition and fetal gestational age 
(Sibai and Barton, 2007). 
 
3. Seizure Prophylaxis with Magnesium sulfate 
Seizures in preeclampsia typically occur at the extreme end of the 
disease. More than 70 years after research has documented the safety and 
efficacy of magnesium sulfate (MgSO4
2-), it continues to be the anticonvulsant of 
choice to prevent or treat seizures caused by preeclampsia (Brichant et al., 2010; 
Mozlemizadeet al., 2011). It is a muscle relaxant that relaxes the uterine and 
cardiac muscles so it keeps the blood pressure down and prevents the 
occurrence of the seizure… it is also a diuretic making them pee. . For seizure 
prophylaxis in patients with severe preeclampsia, the recommended dosage is 4-
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6g load followed by 2-3g/h maintenance. When administered at the 
recommended levels, there are very few side effects when using MgSO4
2-. 
(TABLE 10). However, adverse effects of MgSO4
2- can include complete 
neuromuscular blockade and respiratory depression. Therefore, close monitoring 
after careful administration is imperative. Magnesium sulfate is usually used in 
combination with corticosteroids to help the fetal respiratory system mature. Or 
else the infant may have trouble breathing due to lungs that are not fully formed. 
Once the eclamptic patient is stabilized, the child should be delivered. 
TABLE 12. Recommended Magnesium Sulfate Dosing Guidelines. 
  Loading Dose: Loading Dose: Maintenance: Maintenance: 
Clinical 
Indications 
IM Protocola IV Protocol 
Periodic IM 
Injections 
Continuous 
IV Infusion 
Seizure 
prophylaxis: 
eclampsiab or 
severe 
preeclampsia 
4 g (20%)c IV at 
1 g/min, then 
follow 
immediately 
with IM dosing 
4-6 g (20%) in 
100 mL over 
15-20 min 
10 g (50%)d 5 
g deep IM 
each buttock. 
Repeat every 
4 h 
2-3 g/h 
(20%) 
continued 
until 24 h 
after birth 
Source: McPhee and Papadakis, 2011; Hunter and Gibbins, 2011. 
Abbreviations: IM, intramuscular; IV, intravenous. 
a Initial dose is given via slow IV push. 
bA second bolus of 2 g can be given IV over 3-5 min for acute seizure management. 
cAll IV doses should be diluted to 20% solution. 
dIM doses can be given undiluted (50% solution). 
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4. Other Medications of Choice 
Methyldopa (e.g. Aldomet) and hydralazine (e.g. Apresoline) are the 
antihypertensive medications of choice during pregnancy (Koren, 2004); although 
there are conflicting results in studies whether these drugs have benefits for 
proteinuria, progression to serious disease, and neonatal respiratory syndrome 
(Koren, 2004). Diuretic therapy is particularly indicated for chronically 
hypertensive pregnant women with salt-sensitive hypertension or with evidence 
of left ventricular diastolic dysfunction (LVDD). Nine randomized clinical trials 
concluded that diuretic use protected the specific subset of women with 
hypertension and LVDD from developing preeclampsia (Koren, 2004). 
Angiotensin-converting enzyme (ACE) inhibitors in the 2nd and 3rd trimesters are 
contraindicated because they cause kidney failure in the fetus and other fetal 
complications.  
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IV. DISCUSSION and CONCLUSION 
The World Health Organization recommendations call for a screening 
prediction test that is rapid, non-invasive, widely available, and easy to carry out 
early in gestation. Being able to predict cases of preeclampsia will allow for 
closer surveillance and earlier intervention to improve outcomes, inform methods 
of treatment, and increase evidence-based spending. With all the complexities of 
preeclampsia and all the organ systems it affects and all the complications if 
causes, it may be appropriate to describe preeclampsia as a syndrome rather 
than a single disease or disorder. Standardizing criteria to treat patients with PE 
is problematic due to the widely variable spectrum in how preeclampsia 
develops. While it is unlikely that a single preventive measure or treatment will be 
adequate for all the possible presentations of PE, there are measures that can be 
taken to lessen the degree of severity that is achieved by the disease. Due to 
recent indications that maternal factors combined with biochemical markers 
and/or ultrasound markers could identify women at high-risk as early as the first 
trimester, a randomized trial studying low-dose aspirin at bedtime should be 
considered soon (Bujold, 2011). Despite improvements in the diagnosis and 
management of preeclampsia, severe complications can still occur in both the 
mother and the fetus. Evidently, preeclampsia encompasses a wide spectrum of 
symptoms with unpredictable and sometimes uncontrollable disease progression 
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(Hunter and Gibbins, 2011).Upon researching the topic of preeclampsia, the 
challenges obstetricians face when dealing with a preeclamptic mother-to-be 
became clear rather quickly. Providers across disciplines must work together to 
best treat and care for mothers with preeclampsia.   
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APPENDIX 
APPENDIX A. Weighted number of cases and crude incidence rates, gestational 
hypertension and preeclampsia, 1987-2004. 
 
Source: Wallis et al., 2008. 
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APPENDIX B1. Fetoplacental screening test for pre-eclampsia: findings in the 
published literature. 
 
Fetoplacental Unit 
Placental resistance Placental products 
Uterine artery Doppler Pregnancy-associated plasma protein A 
 Alpha fetoprotein 
 Human chorionic gonadotrophin 
 Oestriol 
 Inhibin A 
 Activin A 
 Placental growth factor 
 Corticotrophin- releasing hormone 
 Placental protein 13 
 Pro- and anti-angiogenic protein ratios 
 Leptin 
Source: Leslie et al., 2011. 
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APPENDIX B2. Maternal screening test for pre-eclampsia: findings in the 
published literature. 
 
Maternal Factors 
Cardiovascular 
status 
Renal 
dysfunction 
Metabolic 
status 
Endothelial 
dysfunction 
Oxidative 
stress or 
hypoxia 
Inflam-
matory 
Mean arterial 
blood pressure 
(MAP) 
Cystatin C Insulin 
resistance 
Endothelin Homo-
cysteine 
C-reactive 
protein 
Mid- trimester 
diastolic blood 
pressure a 
Serum uric 
acid a 
Sex 
hormone 
binding 
globulin 
Plasminogen 
activator 
inhibitor 
Iso-
prostanes 
Pentraxin-
3 
Roll over test a Micro-
albuminuria a 
 Fibronectin Ischaemia 
modified 
albumen 
 
Isometric 
exercise testa 
Urinary 
calcium 
excretiona 
 Vascular cell 
adhesion 
molecule 1 
Anti-oxidant 
status 
 
24- h 
ambulatory 
blood pressure 
monitoring 
Urinary 
kallikrein 
 P and L 
selectin 
  
Intravenous 
infusion of 
angiotensin II a 
Micro-
transferrinuria 
 Platelet 
count 
  
 N-acetyl-β 
glucose-
minidase 
 Throm-
boxane 
  
   Prostacyclin   
   Antithrombin 
III 
  
   C-reactive 
protein 
  
   Antiphos-
pholipid 
antibodies 
  
   Serum lipids   
   Neutrophil 
gelatinase-
associated 
lipocalin 
  
Source: Leslie et al. 2011. 
a show to be of low predictive value. 
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APPENDIX C1. Interventions that are recommended for prevention of 
preeclampsia and eclampsia. 
 
Recommendation 
Quality of 
Evidence 
Strength of 
Recommendation 
In areas where dietary calcium intake is low, 
calcium supplementation during pregnancy (at 
doses of 1.5-2.0 g elemental calcium/day) is 
recommended for the prevention of preeclampsia 
in all women, but especially those at high risk of 
developing preeclampsia. 
Moderate Strong 
Low-dose acetylsalicylic acid (aspirin, 75 mg) is 
recommended for the prevention of preeclampsia 
in women at high risk of developing the condition. 
Moderate Strong 
Low-dose acetylsalicylic acid (aspirin, 75 mg) for 
the prevention of preeclampsia and its related 
complications should be initiated before 20 weeks 
of pregnancy. 
Low Weak 
Magnesium sulfate is recommended for the 
prevention of eclampsia in women with severe 
preeclampsia in preference to other 
anticonvulsants. 
High Strong 
Source: WHO Report, 2011. 
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APPENDIX C2. Interventions that are recommended for treatment of preeclampsia 
and eclampsia. 
 
Recommendation 
Quality 
of 
Evidence 
Strength of 
Recommendation 
Women with severe hypertension during pregnancy 
should receive treatment with antihypertensive 
drugs. 
Very low Strong 
The choice and route of administration of an 
antihypertensive drug for severe hypertension 
during pregnancy, in preference to others, should 
be based primarily on the prescribing clinician's 
experience with that particular drug, its cost and 
local availability. 
Very low Weak 
Magnesium sulfate is recommended for the 
treatment of women with eclampsia in preference 
to other anticonvulsants. 
Moderate Strong 
The full intravenous or intramuscular magnesium 
sulfate regimens are recommended for the 
prevention and treatment of eclampsia. 
Moderate Strong 
For settings where it is not possible to administer 
the full magnesium sulfate regimen, the use of 
magnesium sulfate loading dose followed by 
immediate transfer to a higher level health-care 
facility is recommended for women with severe 
preeclampsia and eclampsia. 
Very low Weak 
Induction of labor is recommended for women with 
severe preeclampsia at a gestational age when the 
fetus is not viable or unlikely to achieve viability 
within one or two weeks. 
Very low Strong 
In women with severe preeclampsia, a viable fetus 
and before 34 weeks of gestation, a policy of 
expectant management is recommended, provided 
that uncontrolled maternal hypertension, increasing 
maternal organ dysfunction or fetal distress are 
absent and can be monitored. 
Very low Weak 
In women with severe preeclampsia, a viable fetus 
and between 34 and 36 (plus 6 days) weeks of 
gestation, a policy of expectant management may 
be recommended, provided that uncontrolled 
maternal hypertension, increasing maternal organ 
dysfunction or fetal distress are absent and can be 
monitored. 
Very low Weak 
In women with severe preeclampsia at term, early 
delivery is recommended. 
Low Strong 
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In women with mild preeclampsia or mild 
gestational hypertension at term, induction of labor 
is recommended.  
Moderate Weak 
In women treated with antihypertensive drugs 
antenatally, continued antihypertensive treatment 
postpartum is recommended. 
Very low Strong 
Treatment with antihypertensive drugs is 
recommended for severe postpartum hypertension. 
Very low Strong 
Source: WHO Report, 2011. 
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APPENDIX C3. Interventions that are not recommended for prevention or 
treatment of preeclampsia and eclampsia. 
 
Recommendation 
Quality 
of 
evidence 
Strength of 
recommendation 
Advice to rest at home is not recommended as an 
intervention for the primary prevention of 
preeclampsia and hypertensive disorders of 
pregnancy in women considered to be at risk of 
developing those conditions. 
Low Weak 
Strict bedrest is not recommended for improving 
pregnancy outcomes in women with hypertension 
(with or without proteinuria) in pregnancy. 
Low Weak 
Restriction in dietary salt intake during pregnancy 
with the aim of preventing the development of 
preeclampsia and its complications is not 
recommended. 
Moderate Weak 
Vitamin D supplementation during pregnancy is not 
recommended to prevent the development of 
preeclampsia and its complications. 
Very Low Strong 
Individual or combined vitamin C and vitamin E 
supplementation during pregnancy is not 
recommended to prevent the development of 
preeclampsia and itscomplications. 
High Strong 
Diuretics, particularly thiazides, are not 
recommended for the prevention of preeclampsia 
and its complications. 
Low Strong 
The use of corticosteroids for the specific purpose 
of treating women with HELLP syndrome is not 
recommended. 
Very Low Weak 
Source: WHO Report, 2011. 
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LIST of JOURNAL ABBREVIATIONS 
 
Acta Clin Belg Acta Clinica Belgica 
Am J Obstet Gynecol American Journal of Obstetrics and 
Gynecology 
 
Am J Hypertens American Journal of Hypertension 
BMC Pregnancy and Childbirth  Boston Medical Center Pregnancy and 
Childbirth 
 
Int J Gynaecol Obstet International Journal of Gynecology and 
Obstetrics 
 
J Biol Chem Journal of Biological Chemistry 
J Matern Fetal Neonatal Med Journal of Maternal-Fetal and Neonatal 
Medicine 
 
J Postgrad Med Journal of Postgraduate Medicine 
J Reprod Med Journal of Reproductive Medicine 
MMWR CDC Surveill Summ Morbidity and Mortality Weekly Report Center 
for Disease Control and Prevention 
Surveillance Summary 
 
N Engl J Med The New England Journal of Medicine 
Obstet Gynecol Obstetrics and Gynecology 
Obstet Gynecol Surv Obstetrical and Gynecological Survey 
Pak J Biol Sci Pakistan Journal of Biological Sciences 
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